TrialAtherosclerosis2016
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Michel Farnier et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
84 papers cite itlatest 60 shown
this paperpooled ittrialcites it